Doravirine Exposure and HIV-1 Suppression after Switching from an Efavirenz-Based Regimen to Doravirine-Lamivudine-Tenofovir Disoproxil Fumarate

被引：3
|
作者：
Greaves, Wayne [1 ]
Wan, Hong [2 ]
Yee, Ka Lai [3 ]
Kandala, Bhargava [3 ]
Vaddady, Pavan [3 ]
Hwang, Carey [1 ]
机构：
[1] Merck & Co Inc, Global Clin Dev Infect Dis, Kenilworth, NJ 07033 USA
[2] Merck & Co Inc, Biostat & Res Decis Sci, Kenilworth, NJ USA
[3] Merck & Co Inc, Pharmacokinet Pharmacodynam & Drug Metab, Kenilworth, NJ USA
来源：
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2019年 / 63卷 / 12期
关键词：
HIV-1; doravirine; efavirenz; efficacy; pharmacokinetics;
D O I：
10.1128/AAC.01298-19
中图分类号：
Q93 [微生物学];
学科分类号：
071005 ; 100705 ;
摘要：
Doravirine is a nonnucleoside reverse transcriptase inhibitor that has been approved for the treatment of HIV-1. In a phase 1 trial, doravirine exposure was transiently decreased when treatment was started immediately after the cessation of efavirenz treatment. In a post hoc subgroup analysis of participants who switched from an efavirenz-based regimen to doravirine-lamivudine-tenofovir disoproxil fumarate in the phase 3 DRIVE-SHIFT trial, doravirine plasma levels at week 4 were similar to noninduced levels, and HIV-1 suppression was maintained at weeks 24 and 48.
引用
收藏
页数：5
相关论文
共 50 条
  • [1] Prophylaxis by doravirine-lamivudine-tenofovir disoproxil fumarate or elvitegravir-cobicistat-emtricitabine-tenofovir alafenamide after sexual exposure to HIV
    Inès Devred
    Kick Kayembe
    Nadia Valin
    Hayette Rougier
    Bruce Wuembulua Shinga
    Sidonie Lambert-Niclot
    Thibault Chiarabini
    Marie-Caroline Meyohas
    Karine Lacombe
    BMC Infectious Diseases, 23
  • [2] Prophylaxis by doravirine-lamivudine-tenofovir disoproxil fumarate or elvitegravir-cobicistat-emtricitabine-tenofovir alafenamide after sexual exposure to HIV
    Devred, Ines
    Kayembe, Kick
    Valin, Nadia
    Rougier, Hayette
    Shinga, Bruce Wuembulua
    Lambert-Niclot, Sidonie
    Chiarabini, Thibault
    Meyohas, Marie-Caroline
    Lacombe, Karine
    BMC INFECTIOUS DISEASES, 2023, 23 (01)
  • [3] Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate for Nonoccupational HIV-1 Postexposure Prophylaxis: A Prospective Open-Label Trial (DORAVIPEP)
    Inciarte, Alexy
    Ugarte, Ainoa
    Martinez-Rebollar, Maria
    Torres, Berta
    Fernandez, Emma
    Berrocal, Leire
    Laguno, Montserrat
    de la Mora, Lorena
    De Lazzari, Elisa
    Callau, Pilar
    Chivite, Ivan
    Gonzalez-Cordon, Ana
    Solbes, Estela
    Rico, Veronica
    Barrero, Laura
    Blanco, Jose Luis
    Martinez, Esteban
    Ambrosioni, Juan
    Mallolas, Josep
    OPEN FORUM INFECTIOUS DISEASES, 2023, 10 (08):
  • [4] Population Pharmacokinetic and Pharmacodynamic Analysis To Evaluate a Switch to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate in People Living with HIV-1
    Vaddady, Pavan
    Kandala, Bhargava
    Yee, Ka Lai
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2020, 64 (11)
  • [5] Comparative Bioavailability of Oral Granule Formulations of the HIV Antiretroviral Drugs Doravirine, Lamivudine, and Tenofovir Disoproxil Fumarate
    Yee, Ka Lai
    DiBenedetto, Adrienne
    Fan, Li
    Khalilieh, Sauzanne
    Triantafyllou, Ilias
    Vallee, Marie-Helene
    Fackler, Paul
    Stoch, S. Aubrey
    Iwamoto, Marian
    AAPS PHARMSCITECH, 2020, 21 (03)
  • [6] Improvement in insulin sensitivity after switching from an integrase inhibitor-based regimen to doravirine/tenofovir disoproxil fumarate/lamivudine in people with significant weight gain
    Calza, Leonardo
    Giglia, Maddalena
    Colangeli, Vincenzo
    Bon, Isabella
    Vitale, Salvatore
    Viale, Pierluigi
    HIV MEDICINE, 2024, 25 (08) : 919 - 926
  • [7] Doravirine/lamivudine/tenofovir disoproxil fumarate in virologically suppressed people living with HIV: A real-life experience
    Calza, Leonardo
    Colangeli, Vincenzo
    Pensalfine, Giulia
    Appolloni, Lucia
    Vitale, Salvatore
    Bon, Isabella
    Viale, Pierluigi
    INTERNATIONAL JOURNAL OF STD & AIDS, 2023, 34 (14) : 1018 - 1023
  • [8] Switching to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains HIV-1 Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial
    Johnson, Margaret
    Kumar, Princy
    Molina, Jean-Michel
    Rizzardini, Giuliano
    Cahn, Pedro
    Bickel, Markus
    Mallolas, Josep
    Zhou, Yan
    Morais, Cristiana
    Kumar, Sushma
    Sklar, Peter
    Hanna, George J.
    Hwang, Carey
    Greaves, Wayne
    Belloso, W.
    Cahn, P. E.
    Cassetti, I.
    Lupo, S. H.
    McMahon, J.
    Finlayson, R.
    Bloch, M.
    Read, T.
    Zoufaly, A.
    Rieger, A.
    Haas, B.
    Vandekerckhove, L.
    Florence, E.
    Dewit, S.
    Derdelinckx, I.
    Vandercam, B.
    Smaill, F.
    Walmsley, S.
    Conway, B.
    Szabo, J.
    Gutierrez, J. Onate
    Gerstoft, J.
    Weis, N.
    Larsen, O.
    Nielsen, H.
    Molina, J-M.
    Raffi, F.
    Reynes, J.
    Yazdanpanah, Y.
    Rockstroh, J.
    Bickel, M.
    Jaeger, H.
    Baumgarten, A.
    Bogner, J.
    Arasteh, K.
    Kern, W.
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2019, 81 (04) : 463 - 472
  • [9] Comparative Bioavailability of Oral Granule Formulations of the HIV Antiretroviral Drugs Doravirine, Lamivudine, and Tenofovir Disoproxil Fumarate
    Ka Lai Yee
    Adrienne DiBenedetto
    Li Fan
    Sauzanne Khalilieh
    Ilias Triantafyllou
    Marie-Helene Vallee
    Paul Fackler
    S. Aubrey Stoch
    Marian Iwamoto
    AAPS PharmSciTech, 21
  • [10] Pharmacokinetics, Tolerability, and Safety of Doravirine and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate Fixed-Dose Combination Tablets in Adolescents Living With HIV: Week 24 Results From IMPAACT 2014
    Melvin, Ann J.
    Yee, Ka Lai
    Gray, Kathryn P.
    Yedla, Mounika
    Wan, Hong
    Tobin, Nicole H.
    Teppler, Hedy
    Campbell, Havilland
    McCarthy, Katie
    Scheckter, Rachel
    Aurpibul, Linda
    Ounchanum, Pradthana
    Rungmaitree, Supattra
    Cassim, Hassena
    McFarland, Elizabeth
    Flynn, Patricia
    Cooper, Ellen
    Krotje, Chelsea
    Townley, Ellen
    Moye, Jack
    Best, Brookie M.
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2023, 92 (02) : 153 - 161
12345